Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821124 | 0.78 | TDP1 (0.44) | KMT2APARP10MAPK1 | |
| SCHEMBL6788802 | 0.78 | LDHA (0.44) | KMT2AMAPK1 | |
| SCHEMBL2213115 | 0.78 | CYP1A2 (0.33) | CYP1A2CYP2C9CYP2C19ALDH1A3KMT2A | |
| SCHEMBL7015768 | 0.77 | MAOA (0.46) | CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL9773249 | 0.77 | LDHA (0.42) | CYP1A2CYP2C9CYP2C19KMT2AMAPK1 | |
| SCHEMBL2096252 | 0.77 | ALDH1A3 (0.52) | CYP1A2CYP2C19ALDH1A3KMT2APARP10 | |
| SCHEMBL5122376 | 0.74 | CYP1A2 (0.30) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1578641 | 0.74 | CYP1A2 (0.30) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3446236 | 0.74 | ALDH1A1 (0.42) | CYP1A2CYP2C9CYP2C19ALDH1A3KMT2A | |
| SCHEMBL28475690 | 0.74 | KEAP1 (0.49) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598349-B1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD KK (JP) | 2011-07-27 | — | — | EP | claimed |
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-1598349-B1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD KK (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | CYP1A2 1518/4885CYP2C9 2169/4885CYP2C19 2297/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | CYP1A2 1602/4885CYP2C9 2234/4885CYP2C19 2361/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | CYP1A2 1518/4885CYP2C9 2169/4885CYP2C19 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.